James P. Allison

Q: What Schools Are Affiliated With James P. Allison

James P. Allison is affiliated with the following schools: University of California, Berkeley, University of Texas at Austin, MD Anderson Cancer Center, University of California, San Diego, Baylor College of Medicine, University of Massachusetts Medical School, University of Toronto, University of California, San Francisco, University of Portland, University of Edinburgh, Stanford University, Georgetown University, Oregon Health & Science University, Okayama University, University of Texas Southwestern Medical Center

James P. Allison's AcademicInfluence.com Rankings

James P. Allison

Biology

#93

World Rank

#167

Historical Rank

#53

USA Rank

Immunology

World Rank

Historical Rank

USA Rank

biology Degrees

Download Badge

Biology

James P. Allison's Degrees

PhD Biological Science University of Texas at Austin
Bachelors Microbiology University of Texas at Austin

Why Is James P. Allison Influential?

(Suggest an Edit or Addition)

According to Wikipedia, James Patrick Allison is an American immunologist and Nobel laureate who holds the position of professor and chair of immunology and executive director of immunotherapy platform at the MD Anderson Cancer Center at the University of Texas.

(See a Problem?)

James P. Allison's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Restoring function in exhausted CD8 T cells during chronic viral infection (2006) (3786)
The future of immune checkpoint therapy (2015) (3376)
Enhancement of Antitumor Immunity by CTLA-4 Blockade (1996) (3262)
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients (2018) (2594)
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation (1995) (2032)
Immunologic correlates of the abscopal effect in a patient with melanoma. (2012) (1745)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential (2015) (1722)
CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones (1992) (1679)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. (2018) (1656)
Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens (2014) (1612)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors (2010) (1599)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma (2003) (1591)
Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. (1993) (1288)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma (2013) (1191)
Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. (2014) (1182)
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research (2009) (1171)
Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses (2001) (1129)
Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting (2012) (1076)
B cells and tertiary lymphoid structures promote immunotherapy response (2020) (1046)
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation (1999) (1026)
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. (2001) (982)
ICOS co-stimulatory receptor is essential for T-cell activation and function (2001) (979)
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients (2003) (979)
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells (1996) (949)
CTLA-4: new insights into its biological function and use in tumor immunotherapy (2002) (941)
Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. (2015) (890)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy (2016) (860)
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. (2005) (856)
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies (2009) (830)
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1 (2003) (821)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade (2017) (819)
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts (2010) (748)
Cancer classification using the Immunoscore: a worldwide task force (2012) (719)
The emerging role of CTLA-4 as an immune attenuator. (1997) (690)
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. (2016) (685)
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. (2006) (653)
Epithelial to Mesenchymal Transition induces cell cycle arrest and parenchymal damage in renal fibrosis (2015) (651)
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients (2008) (644)
Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. (1981) (635)
A comparison of fecal occult-blood tests for colorectal-cancer screening. (1996) (615)
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. (2015) (601)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy (2014) (598)
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells (2003) (584)
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity (2016) (583)
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps (2011) (578)
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance (2017) (555)
Developmentally ordered appearance of thymocytes expressing different T-cell antigen receptors (1988) (543)
Checkpoint blockade in cancer immunotherapy. (2007) (528)
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 (2013) (524)
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. (2002) (518)
Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. (1982) (505)
Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma (2018) (500)
Limited diversity of γδ antigen receptor genes of thy-1+ dendritic epidermal cells (1988) (492)
Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido (2011) (483)
Co-stimulation in T cell responses. (1997) (459)
Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. (2000) (443)
CTLA-4-Mediated inhibition of early events of T cell proliferation. (1999) (441)
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. (2006) (438)
Immune modulation in cancer with antibodies. (2014) (435)
Costimulatory regulation of T cell function. (1999) (428)
B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. (2004) (420)
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial (2010) (409)
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer (2017) (409)
Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. (2007) (409)
Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. (1997) (408)
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis (2018) (400)
CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. (1998) (399)
Epitope landscape in breast and colorectal cancer. (2008) (396)
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer (2007) (396)
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. (1997) (390)
B7x: A widely expressed B7 family member that inhibits T cell activation (2003) (370)
Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? (2019) (357)
Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer (2017) (355)
Identification and distribution of the costimulatory receptor CD28 in the mouse. (1992) (353)
Recognition of self antigens by skin-derived T cells with invariant gamma delta antigen receptors. (1991) (346)
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. (2015) (342)
The B7 Family and Cancer Therapy: Costimulation and Coinhibition (2007) (339)
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit (2008) (335)
CD28-B7 interactions in T-cell activation. (1994) (332)
Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Regulates the Unfolding of Autoimmune Diabetes (1998) (329)
Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine (2001) (328)
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab (2011) (323)
The immunobiology of T cells with invariant γδ antigen receptors (1991) (323)
Origin of Thy-1+ dendritic epidermal cells of adult mice from fetal thymic precursors (1990) (318)
CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help (1993) (315)
Expression of Helios in Peripherally Induced Foxp3+ Regulatory T Cells (2012) (291)
Aire-Dependent Thymic Development of Tumor-Associated Regulatory T Cells (2013) (290)
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. (2017) (287)
Alternative Activation Is an Innate Response to Injury That Requires CD4+ T Cells to be Sustained during Chronic Infection1 (2007) (284)
TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo (2010) (284)
Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function (2007) (283)
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. (2018) (280)
Immune Checkpoint Blockade in Cancer Therapy (2008) (277)
Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. (2012) (273)
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting (2010) (270)
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma (2013) (265)
The effect of fecal occult-blood screening on the incidence of colorectal cancer. (2001) (262)
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors? (2014) (260)
Structure, function, and serology of the T-cell antigen receptor complex. (1987) (250)
Augmentation of T Cell Levels and Responses Induced by Androgen Deprivation1 (2004) (244)
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. (1999) (241)
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication (2011) (237)
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. (2008) (237)
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy (2014) (235)
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. (2010) (235)
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers (2018) (231)
Expression and function of the CD3-antigen receptor on murine CD4+8+ thymocytes (1987) (230)
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome (2007) (228)
Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. (2012) (227)
Stool DNA and Occult Blood Testing for Screen Detection of Colorectal Neoplasia (2008) (225)
Distinct antigen receptor repertoires of two classes of murine epithelium-associated T cells (1989) (224)
The Role of CTLA‐4 in the Regulation and Initiation of T‐Cell Responses (1996) (224)
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) (215)
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma (2008) (214)
Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy (2008) (212)
Role of Thiopurine and Anti-TNF Therapy in Lymphoma in Inflammatory Bowel Disease (2011) (211)
Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). (2010) (207)
Dissecting the mechanisms of immune checkpoint therapy (2020) (204)
Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production (2011) (202)
The mouse T cell receptor: Structural heterogeneity of molecules of normal T cells defined by Xenoantiserum (1983) (202)
Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections (2009) (200)
T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. (2007) (196)
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas (2010) (195)
Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein. (1997) (193)
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. (2018) (193)
The Next Decade of Immune Checkpoint Therapy. (2021) (190)
Regulation of T-cell receptor γ-chain RNA expression in murine Thy-1+ dendritic epidermal cells (1987) (189)
Manipulation of costimulatory signals to enhance antitumor T-cell responses. (1995) (186)
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer (2019) (184)
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response (2021) (181)
Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies (2019) (179)
The Yin and Yang of T Cell Costimulation (1995) (178)
The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia (2018) (177)
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma (2019) (177)
Strength of TCR–Peptide/MHC Interactions and In Vivo T Cell Responses (2011) (174)
Challenges and possible solutions to colorectal cancer screening for the underserved. (2014) (170)
Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy (2013) (168)
Thymocyte development is normal in CTLA-4-deficient mice. (1997) (167)
In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. (1999) (167)
Two signals are required for negative selection of CD4+CD8+ thymocytes. (1993) (164)
Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. (1994) (162)
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. (2017) (160)
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities (2016) (160)
A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. (2012) (157)
Incidence and Prevalence of Inflammatory Bowel Disease in a Northern California Managed Care Organization, 1996–2002 (2008) (157)
Population Screening for Colorectal Cancer Means Getting FIT: The Past, Present, and Future of Colorectal Cancer Screening Using the Fecal Immunochemical Test for Hemoglobin (FIT) (2014) (156)
Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know (2015) (153)
Advances in Fecal Occult Blood Tests: The FIT Revolution (2014) (153)
Single dose of anti–CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance (2010) (152)
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin (2012) (152)
Defining the critical hurdles in cancer immunotherapy (2011) (152)
The TRAMP Mouse as a Model for Prostate Cancer (2001) (149)
Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. (1996) (147)
Limited diversity of T-cell receptor gamma-chain expression of murine Thy-1+ dendritic epidermal cells revealed by V gamma 3-specific monoclonal antibody. (1989) (147)
T-cell activation: integration of signals from the antigen receptor and costimulatory molecules. (1995) (145)
Cancer immunotherapy: co‐stimulatory agonists and co‐inhibitory antagonists (2009) (143)
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. (2008) (142)
The T cell antigen receptor complex expressed on normal peripheral blood CD4-, CD8- T lymphocytes. A CD3-associated disulfide-linked gamma chain heterodimer (1987) (141)
Monoclonal antibodies in cancer therapy. (2012) (141)
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy (2018) (138)
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes (2018) (137)
Correlation of cell surface antigen expression on human thymocytes by multi-color flow cytometric analysis: implications for differentiation. (1986) (136)
The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. (1990) (135)
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling (2016) (135)
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. (2017) (134)
Hemoccult screening in detecting colorectal neoplasm: sensitivity, specificity, and predictive value. Long-term follow-up in a large group practice setting. (1990) (132)
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. (2004) (130)
Secondary but not primary T cell responses are enhanced in CTLA‐4‐deficient CD8+ T cells (1998) (130)
Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. (2009) (129)
Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals (2010) (128)
Clustering of Inflammatory Bowel Disease With Immune Mediated Diseases Among Members of a Northern California-Managed Care Organization (2007) (127)
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade (2020) (127)
Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in Northern California, 1996 to 2006. (2010) (127)
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma (2020) (127)
B7 Expression on T Cells Down-Regulates Immune Responses through CTLA-4 Ligation via R-T Interactions1 (2004) (126)
CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells. (1994) (122)
Murine Ia and human DR antigens: homology of amino-terminal sequences. (1978) (122)
Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. (2000) (121)
Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. (1999) (120)
T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine. (2011) (117)
Limited diversity of gamma delta antigen receptor genes of Thy-1+ dendritic epidermal cells. (1988) (116)
Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity (2020) (115)
Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis. (2011) (114)
Activation and differentiation requirements of primary T cells in vitro. (1993) (113)
Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis (1997) (112)
Comprehensive T cell repertoire characterization of non-small cell lung cancer (2020) (110)
Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy (2016) (109)
Engagement of NKG2D by Cognate Ligand or Antibody Alone Is Insufficient to Mediate Costimulation of Human and Mouse CD8+ T Cells1 (2005) (107)
CTLA-4 Overexpression Inhibits T Cell Responses through a CD28-B7-Dependent Mechanism1 (2006) (107)
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma (2017) (105)
Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability (2007) (103)
Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities (2019) (102)
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity (2017) (102)
Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients (2013) (101)
Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8+ T Lymphocytes (2008) (99)
Attenuated T Cell Responses to a High-Potency Ligand In Vivo (2010) (99)
Estimation of the Period Prevalence of Inflammatory Bowel Disease Among Nine Health Plans Using Computerized Diagnoses and Outpatient Pharmacy Dispensings (2007) (98)
Repression of B7.2 on Self-reactive B Cells Is Essential to Prevent Proliferation and Allow Fas-mediated Deletion by CD4+ T Cells (1998) (97)
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 (2015) (97)
Monoclonal antibodies recognizing oval cells induced in the liver of rats by N-2-fluorenylacetamide or ethionine in a choline-deficient diet. (1985) (97)
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model (2012) (96)
Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. (2009) (95)
Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans (2012) (95)
Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade (2018) (94)
The immunobiology of T cells with invariant gamma delta antigen receptors. (1991) (91)
CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases (2011) (89)
CD28 disruption exacerbates inflammation in Tgf-beta1-/- mice: in vivo suppression by CD4+CD25+ regulatory T cells independent of autocrine TGF-beta1. (2004) (89)
Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. (2007) (89)
Epidemiologic observations of influenza B virus infections in Houston, Texas, 1976-1977. (1980) (88)
Biologic and chemical characterization of HLA antigens in human serum. (1977) (88)
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer (2020) (87)
CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. (1997) (86)
Phenotypic analysis and γδ-T cell receptor repertoire of murine T cells associated with the vaginal epithelium (1991) (84)
The emerging role of immune checkpoint based approaches in AML and MDS (2018) (83)
Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice (2002) (83)
Cloned natural suppressor cell lines express the CD3+CD4-CD8- surface phenotype and the alpha, beta heterodimer of the T cell antigen receptor. (1989) (83)
Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses (2012) (82)
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes (2017) (82)
A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention. (2020) (82)
Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. (2008) (81)
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 (2015) (81)
Identification of a novel T cell surface disulfide-bonded dimer distinct from the alpha/beta antigen receptor. (1987) (79)
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy (2016) (78)
Colonoscopy vs. Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM): Rationale for Study Design (2017) (77)
Strategies for combining immunotherapy with radiation for anticancer therapy. (2015) (77)
Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells. (2000) (77)
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. (2019) (74)
The Role of B7 Costimulation in CD4/CD8 T Cell Homeostasis (2000) (73)
Cytotoxic T Lymphocyte Antigen-4 Blockade Enhances Antitumor Immunity by Stimulating Melanoma-Specific T-cell Motility (2014) (73)
Identification of antigen receptor-associated structures on murine T cells (1985) (73)
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. (2019) (72)
Delta is the C x-gene product in the γ/δ antigen receptor of dendritic epidermal cells (1987) (72)
Group A Streptococcus Gene Expression in Humans and Cynomolgus Macaques with Acute Pharyngitis (2003) (71)
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine (2015) (71)
Itk Negatively Regulates Induction of T Cell Proliferation by CD28 Costimulation (1997) (69)
Immune Checkpoint Blockade in Cancer Therapy: The 2015 Lasker-DeBakey Clinical Medical Research Award. (2015) (68)
The T-cell antigen receptor gamma gene: rearrangement and cell lineages. (1987) (66)
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses (2019) (65)
T cell-mediated elimination of B7.2 transgenic B cells. (1997) (64)
Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity (2008) (64)
Tissue-specific expression of B7x protects from CD4 T cell–mediated autoimmunity (2011) (63)
A subset of T cell receptors associated with L3T4 molecules mediates C6VL leukemia cell binding of its cognate retrovirus (1987) (63)
Breaking down the barriers to cancer immunotherapy (2005) (62)
Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein (2013) (62)
Genetic Diversity among Type emm28 Group A Streptococcus Strains Causing Invasive Infections and Pharyngitis (2005) (62)
Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) (2016) (61)
Lack of a role for transforming growth factor-β in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation (2001) (60)
Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. (2007) (60)
Negative Co‐stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States (2019) (60)
Insolubilization of L-asparaginase by covalent attachment to nylon tubing. (1972) (59)
The role of short homology repeats and TdT in generation of the invariant γδ antigen receptor repertoire in the fetal thymus (1995) (58)
Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. (1996) (58)
ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC (2020) (58)
Co‐stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily (2005) (57)
Quality Of Life Measurement Clarifies The Cost-Effectiveness Of Helicobacter Pylori Eradication In Peptic Ulcer Disease And Uninvestigated Dyspepsia (2001) (57)
Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial (2016) (56)
Regulated Costimulation in the Thymus Is Critical for T Cell Development: Dysregulated CD28 Costimulation Can Bypass the Pre-TCR Checkpoint (2005) (56)
Identification of dipeptidyl peptidase IV as a protein shared by the plasma membrane of hepatocytes and liver biomatrix. (1985) (55)
Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report (2016) (55)
T cell receptor-triggered activation of intraepithelial lymphocytes in vitro. (1993) (55)
Comparing fecal immunochemical tests: improved standardization is needed. (2012) (55)
B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]. (2004) (54)
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies (2017) (54)
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade (2008) (54)
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma (2016) (53)
Colon Cancer Screening Guidelines 2005: the fecal occult blood test option has become a better FIT. (2005) (52)
B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. (2015) (51)
Human DR (Ia-like) antigens: biological and molecular profile. (1978) (51)
ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection. (2016) (51)
668 A RANDOMIZED PHASE II STUDY OF IPILIMUMAB WITH ANDROGEN ABLATION COMPARED WITH ANDROGEN ABLATION ALONE IN PATIENTS WITH ADVANCED PROSTATE CANCER (2010) (50)
γδ T-cell development (1993) (49)
Enhancement of the anti‐tumor immune response using a combination of interferon‐γ and B7 expression in an experimental mammary carcinoma (1998) (49)
Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. (2010) (48)
Nuclear events after activation of CD4+8+ thymocytes. (1990) (48)
Phenotypic and functional analysis of γδ T cell receptor-positive murine dendritic epidermal clones (1989) (48)
Role of IL-6, IL-1, and CD28 signaling in responses of mouse CD4+ T cells to immobilized anti-TCR monoclonal antibody. (1994) (47)
Excerpts from Unlocking Our Future: Toward a New National Science Policy (1999) (46)
Characterization of a family of glycoproteins associated with the bile canalicular membrane of normal hepatocytes but not expressed by two transplantable rat hepatocellular carcinomas. (1983) (45)
Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. (2006) (45)
Reactogenicity and immunogenicity of bivalent influenza A and monovalent influenza B virus vaccines in high-risk children. (1977) (44)
Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade (2017) (44)
Cutting Edge: A Crucial Role for B7-CD28 in Transmitting T Help from APC to CTL (2002) (43)
Immunological Insights from Patients Undergoing Surgery on Ipilimumab for Metastatic Melanoma (2013) (43)
Validity of computerized diagnoses, procedures, and drugs for inflammatory bowel disease in a northern California managed care organization (2009) (43)
Photodegradation of poly(methyl methacrylate) (1966) (43)
Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma (2019) (42)
Augmented IL-15Rα Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice (2012) (42)
Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells (2004) (42)
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. (2022) (41)
Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—Response (2019) (41)
TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion (2019) (41)
Expression of T cell antigen receptor beta-chains on subsets of mouse thymocytes. Analysis by three-color flow cytometry. (1987) (41)
Intrathymic differentiation of V gamma 3 T cells (1993) (40)
Gastroenterologists' attitudes and self‐reported practices regarding inflammatory bowel disease (2008) (39)
Friends Not Foes: CTLA-4 Blockade and mTOR Inhibition Cooperate during CD8+ T Cell Priming To Promote Memory Formation and Metabolic Readiness (2015) (39)
Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC. (2019) (39)
Navigating the murky waters of colorectal cancer screening and health reform. (2014) (39)
CD 28 and CTLA-4 Have Opposing Effects on the Response of T ceils to Stimulation (2003) (38)
Potential Intended and Unintended Consequences of Recommending Initiation of Colorectal Cancer Screening at Age 45 Years. (2018) (38)
Immunobiological properties of 1-butanol-extracted cell surface antigens. (1981) (38)
CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection (2012) (38)
Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC. (2019) (38)
Improving the reporting of evaluations of faecal immunochemical tests for haemoglobin: the FITTER standard and checklist. (2015) (38)
Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. (2010) (37)
A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance? (2007) (37)
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. (2022) (37)
Distribution and ontogeny of CD2 expression by murine T cells. (1989) (36)
Immunotherapeutic strategies for high-risk bladder cancer. (2007) (36)
Pillars article: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. The journal of experimental medicine. 1995. 182: 459-465. (2011) (36)
Murine T cells with invariant gamma delta antigen receptors: origin, repertoire, and specificity. (1991) (35)
Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study (2019) (35)
Cutting Edge: A Crucial Role for B7-CD28 in Transmitting T Help from APC to CTL1 (2002) (35)
HL-A antigens in serum and urine: isolation, characterization, and immunogenic properties. (1976) (35)
Defining the Immune Checkpoint Landscape in Patients (pts) with Acute Myeloid Leukemia (AML) (2016) (35)
Characterization of neutrophils and T lymphocytes associated with the murine vaginal epithelium. (1993) (34)
Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. (2009) (34)
Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer (2015) (33)
Gene Therapy-Mediated Reprogramming Tumor Infiltrating T Cells Using IL-2 and Inhibiting NF-κB Signaling Improves the Efficacy of Immunotherapy in a Brain Cancer Model (2012) (33)
High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer (2019) (33)
Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML. (2017) (32)
Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells. (2007) (31)
Association of the diversity and composition of the gut microbiome with responses and survival (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy. (2017) (31)
Physical association of histocompatibility antigens and tumor-associated antigens on the surface of murine lymphoma cells. (1979) (31)
Screening for Colorectal Cancer in a Safety-Net Health Care System: Access to Care Is Critical and Has Implications for Screening Policy (2009) (31)
Screening tests for colorectal cancer: A menu of options remains relevant (2006) (31)
A randomized controlled trial of test-and-treat strategy for Helicobacter pylori: clinical outcomes and health care costs in a managed care population receiving long-term acid suppression therapy for physician-diagnosed peptic ulcer disease. (2003) (31)
The role of tyrosine phosphorylation and PTP‐1C in CTLA‐4 signal transduction (1996) (31)
Inducible costimulator is required for type 2 antibody isotype switching but not T helper cell type 2 responses in chronic nematode infection. (2005) (30)
Vaccination with Tumor Cells Expressing IL-15 and IL-15Rα Inhibit Murine Breast and Prostate Cancer (2014) (30)
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies (2017) (30)
The Murine T Cell Antigen Receptor and Associated Structures (1984) (30)
Immunoprecipitation of pyrimidine(6-4)pyrimidone photoproducts and cyclobutane pyrimidine dimers in uv-irradiated DNA. (1990) (30)
Distinct epitopes on the T cell antigen receptor of HPB-ALL tumor cells identified by monoclonal antibodies. (1986) (30)
B7x in the Periphery Abrogates Pancreas-Specific Damage Mediated by Self-reactive CD8 T Cells (2012) (30)
LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy (2021) (29)
H–2 Antigens on a murine lymphoma are associated with additional proteins (1978) (29)
Frontiers in cancer immunotherapy—a symposium report (2020) (29)
Neoadjuvant relatlimab and nivolumab in resectable melanoma (2022) (29)
B7 Expression on T Cells Down-Regulates Immune Responses through CTLA-4 Ligation via R-T Interactions. (2004) (29)
[55] HLA antigens in serum (1984) (28)
Alpha/beta T-cell antigen receptor gene and protein expression occurs at early stages of thymocyte differentiation. (1988) (28)
Characterization and Comparison of GITR Expression in Solid Tumors (2019) (28)
Checkpoints (2015) (28)
A standard for Faecal Immunochemical TesTs for Haemoglobin Evaluation Reporting (FITTER) (2014) (28)
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck (2021) (28)
Antibodies against the T cell receptor/CD3 complex interfere with distinct intra‐thymic cell‐cell interactions in vivo: correlation with arrest of T cell differentiation (1989) (28)
Serologic and immunochemical characterization of HLA-A9 xenoantisera. (1978) (28)
Regulation of T-cell receptor gamma-chain RNA expression in murine Thy-1+ dendritic epidermal cells. (1987) (28)
De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute (2016) (27)
Phenotypic analysis and gamma delta-T cell receptor repertoire of murine T cells associated with the vaginal epithelium. (1991) (27)
Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) (2018) (27)
A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation (2018) (27)
Functionally anergic lpr and gld B220+ T cell receptor (TCR)-alpha/beta+ double-negative T cells express CD28 and respond to costimulation with phorbol myristate acetate and antibodies to CD28 and the TCR. (1993) (25)
Immunogenicity of HLA antigens purified from serum. (1977) (25)
CTLA-4--the costimulatory molecule that doesn't: regulation of T-cell responses by inhibition. (1999) (25)
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer (2021) (25)
Expression of a fetal γδ T-cell receptor in adult mice triggers a non-MHC-linked form of selective depletion (1991) (24)
Cell surface expression by adult rat hepatocytes of a non-collagen glycoprotein present in rat liver biomatrix. (1984) (24)
Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner (2019) (24)
Recommendations for a step‐wise comparative approach to the evaluation of new screening tests for colorectal cancer (2016) (24)
T cells specific for α-myosin drive immunotherapy-related myocarditis (2022) (23)
Chemical and immunological characterization of developmentally expressed chicken erythroid surface membrane antigens. (1982) (22)
Altered expression of lymphocyte differentiation antigens on phorbol ester-activated CD4+8+ T cells. (1988) (22)
Phenotypic and functional analysis of positive selection in the gamma/delta T cell lineage (1993) (21)
Replacing the Guaiac Fecal Occult Blood Test With the Fecal Immunochemical Test Increases Proportion of Individuals Screened in a Large Healthcare Setting (2017) (21)
To be or not to be B7. (2006) (21)
Window-of-opportunity clinical trial of a PD-1 inhibitor in patients with recurrent glioblastoma. (2018) (20)
A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early-stage/resectable breast cancer (ESBC). (2013) (20)
The lymphoproliferative defect in CTLA-4-deficient mice is ameliorated by an inhibitory NK cell receptor. (2002) (20)
The immunobiology of γδ+ T cells (1990) (19)
Quantitation of hemoglobin improves fecal immunochemical tests for noninvasive screening. (2013) (19)
Gamma delta T cells in murine epithelia: origin, repertoire, and function. (1991) (19)
B7 Expression on T Cells Down-Regulates Immune Responses through CTLA-4 Ligation via R-T Interactions. (2004) (18)
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4 (2013) (18)
Cytotoxic T lymphocyte antigen 4 (CD152) regulates self-reactive T cells in BALB/c but not in the autoimmune NOD mouse. (2000) (18)
Expression of a T cell receptor gamma-chain (V gamma 1.1J gamma 4C gamma 4) transgene in mice influences T cell receptor ontogeny and thymic architecture during development. (1990) (18)
Making colorectal cancer screening FITTER for purpose with quantitative faecal immunochemical tests for haemoglobin (FIT) (2013) (18)
Racial and Ethnic Differences in Health Care Utilization and Outcomes Among Ulcerative Colitis Patients in an Integrated Health-Care Organization (2014) (18)
The best screening test for colorectal cancer is the one that gets done well. (2010) (18)
FIT Testing: An Overview (2013) (18)
Biosynthesis and processing of murine T-cell antigen receptor (1984) (17)
Colorectal cancer screening guidelines: the importance of evidence and transparency. (2010) (17)
Repression of B 7 . 2 on Self-reactive B Cells Is Essential to Prevent Proliferation and Allow Fas-mediated Deletion by CD 4 1 T Cells (1998) (16)
Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study (2018) (16)
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy (2021) (16)
Detection of H-2 antigens in serum. (1975) (16)
Co-stimulation via CD28 induces activation of a refractory subset of MRL-lpr/lpr T lymphocytes. (1993) (16)
Editorial: FIT: A Valuable but Underutilized Screening Test for Colorectal Cancer—It's Time for a Change (2010) (16)
Phase IB/II study of lirilumab with azacytidine (AZA) in relapsed AML. (2017) (15)
Inhibitors of B7-CD28 costimulation in urologic malignancies. (2009) (15)
A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy (CN), metastasectomy (MS) or post-treatment biopsy (Bx). (2018) (15)
Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AML (2017) (15)
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment (2021) (15)
Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma. (2018) (15)
Association of diversity and composition of the gut microbiome with differential responses to PD-1 based therapy in patients with metastatic melanoma. (2017) (15)
Partial amino acid sequence of HLA-A9 antigen purified with a specific xenoantiserum. (1978) (14)
Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia (2017) (14)
Resolution and partial characterization of the major plasma membrane sialoglycoproteins of Novikoff tumor cells. (1979) (14)
Hybridomas and Cellular Immortality (1983) (14)
A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptors. (2006) (14)
A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC). (2019) (14)
Cost benefits of hemoccult screening for colorectal carcinoma (1985) (14)
Chicken fetal and adult antigen expression on erythroleukemia cells before and after induced differentiation. (1982) (14)
Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe". (2012) (14)
Biochemical evidence for expression of a semi-allogeneic, H-2 antigen by a murine adenocarcinoma. (1983) (13)
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma (2020) (13)
Intrathymic Differentiation of V ' y 3 T Cells (2003) (13)
First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors (2021) (13)
Expression and function of cd3 on murine thymocytes (1988) (12)
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer (2021) (12)
The gamma T-cell antigen receptor (1987) (12)
Screening for colorectal cancer 2003: is there still a role for the FOBT? (2003) (12)
Immunochemical characterization of differentiation and age-related cell surface antigens expressed by chicken erythrocytes. (1984) (12)
The role of short homology repeats and TdT in generation of the invariant gamma delta antigen receptor repertoire in the fetal thymus. (1995) (12)
Yield of Colonoscopy After a Positive Result From a Fecal Immunochemical Test OC‐Light (2018) (12)
HLA antigens in serum. (1984) (12)
Newer fecal tests: opportunities for professionals in laboratory medicine. (2012) (12)
Monoclonal antibody to chicken fetal antigens on normal erythroid cells and hematopoietic-lymphoid tumor cell lines. (1982) (12)
Gamma delta T-cell development. (1993) (11)
Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts). (2019) (11)
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma (2018) (11)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy (2022) (10)
Measurement of Colorectal Cancer Test Use With Medical Claims Data in a Safety-Net Health System (2013) (10)
New screening guidelines for colorectal cancer: a practical guide for the primary care physician. (2009) (10)
MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4). (2004) (10)
An open invitation to the cancer immunology community. (2012) (10)
Diminished expression of the T cell receptor on the expanded lymphocyte population in MRL/Mp-lpr/lpr mice. (1989) (9)
Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis (2018) (9)
Nobels: Toll pioneers deserve recognition (2011) (9)
Response to Comment on “Expression of Helios in Peripherally Induced Foxp3+ Regulatory T Cells” (2012) (9)
Prostate cancer: advances in immunotherapy. (2003) (9)
Endotoxin-stimulated immune response to modified lymphoma cells. (1975) (8)
Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration. (2022) (8)
Limited diversity of T-cell receptor y-chain expression of murine Thy-1+ dendritic epidermal cells revealed by Vy3-specific monoclonal antibody (2003) (8)
Checkpoint Expression By Acute Myeloid Leukemia (AML) and the Immune Microenvironment Suppresses Adaptive Immunity (2017) (8)
Cytotoxic T lymphocyte antigen-4 ( CTLA-4 ) regulates primary and secondary peptide-specific CD 4 1 T cell responses ( CD 152 y inhibitory costimulation y homeostasis y tolerance ) (1999) (8)
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma (2021) (7)
Characterization of env gene recombination in X‐ray‐induced thymomas of C57BL76 mice (1989) (7)
Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. (2019) (7)
Phenotypic and functional analysis of gamma delta T cell receptor-positive murine dendritic epidermal clones. (1989) (7)
γδ Antigen receptors of Thy-1 + dendritic epidermal cells: Implications for thymic differentiation (1988) (7)
Abstract 3205: Defining the immune checkpoint landscape of acute myeloid leukemia (AML) (2016) (7)
Cutting Edge: Chronic Inflammatory Liver Disease in Mice Expressing a CD28-Specific Ligand (2013) (7)
A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx). (2019) (6)
Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using FIT (2014) (6)
Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity (2017) (6)
Colonic Polyps: The Harm of Overdiagnosis (2012) (6)
Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response (2020) (6)
Phenotypic and Functional Analysis of Positive Selection in the T Cell Lineage (2003) (6)
Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer (2012) (6)
Phenotypic and Functional Analysis of Positive Selection in the T Cell Lineage By Faith B. Wells,* Yoichi Tatsumi, t Jeffrey A. Bluestone, t (1993) (5)
Synergy of TLR4 agonist GSK1795091, an innate immune activator, with agonistic antibody against co-stimulatory immune checkpoint molecule OX40 in cancer immunotherapy. (2018) (5)
Abstract P2-15-01: Integrated immunologic assessment of tumor infiltrating lymphocytes (TILs) and peripheral blood to assess synergy of cryoablation (cryo) plus ipilimumab (ipi) in early stage breast cancer (ESBC) patients (pts) (2015) (5)
Hokusei Jo Gakko Annual Reports in the 1911-1923 Hokkaido Station Reports to the Japan Mission of the Board of Foreign Missions of the Presbyterian Church in the United States of America (2013) (5)
Abstract 2672: Response to anti-PD-1 based therapy in metastatic melanoma patients is associated with the diversity and composition of the gut microbiome (2017) (5)
Abstract A205: Effects of anti-CTLA-4 and anti-PD-1 on memory T-cell differentiation and resistance to tumor relapse (2017) (5)
A Phase 2 Study of Nivolumab Combined with Ibrutinib in Patients with Diffuse Large B-cell Richter Transformation of CLL. (2022) (5)
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma (2018) (5)
Pillars Article: Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. 1982, J. Immunol. 129: 2293–2300. (2005) (5)
Screening for colorectal cancer. (2001) (4)
A New Tilt on Computer Generated Space Situation Displays (1984) (4)
The imperative of equal funding for studies that evaluate any of the evidence-based, guideline-recommended colorectal cancer screening tests. (2009) (4)
The importance of comparing quantitative faecal immunochemical tests (FIT) before selecting one for a population-based colorectal cancer screening programme (2018) (4)
T-cell receptor (TCR) DNA deep sequencing to evaluate clonality of tumor-infiltrating lymphocytes (TILs) in early-stage breast cancer patients (pts) receiving preoperative cryoablation (cryo) and/or ipilimumab (ipi). (2014) (4)
A novel gamma delta T cell receptor for antigen adds limited diversity to the gamma delta repertoire in adult thymus. (1989) (4)
Nivolumab (Nivo) in Combination with Azacytidine (AZA) in Relapsed and Frontline Elderly Acute Myeloid Leukemia (AML): Abstract: CI‐026 (2017) (4)
Why What You May Not Know About Fecal Immunochemical Testing Matters (2019) (4)
The Role of Fecal Occult Blood Testing in Screening for Colorectal Cancer COLORECTAL CANCER: AN UPDATE FOR DIAGNOSIS AND PREVENTION, SERIES #3 (2007) (4)
Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM) (2015) (4)
The polymerization of propiolamide (1966) (3)
Delta is the Cx-gene product in the gamma/delta antigen receptor of dendritic epidermal cells. (1987) (3)
Immunologic profiling of consensus molecular subtype (CMS) stratified colorectal cancer (CRC) primary and liver metastectomy specimens: Implications for immune targeting of proficient mismatch repair CRC. (2016) (3)
Association of phosphatidylinositol 3-kinase (PI3K) pathway activation with increased immune checkpoint expression in colorectal cancer (CRC) patients. (2018) (3)
Prostate Cancer (2003) (3)
Manipulation of T Cell Activation in the Anti-Tumor Immune Response (1998) (3)
Cytotoxic T cells specific for alpha-myosin drive immunotherapy related myocarditis (2022) (3)
Reduction of immature myeloid cells by treatment with all-trans-retinoic acid (ATRA) improves the immunotherapeutic effect of the combination of local radiation with CTLA-4 blockade (2004) (3)
Structural differences in envelope glycoproteins associated with rat leukaemia virus produced by Novikoff hepatocellular carcinoma and spontaneously transformed Wistar rat embryo cells. (1984) (3)
Immune co-signaling to treat cancer (2013) (3)
The immunobiology of gamma delta+ T cells. (1990) (3)
Test and treat for H.pylori clinical outcomes in an HMO population on chronic acid suppression therapy for physician diagnosed peptic ulcer disease (2000) (3)
Adding new fecal occult blood tests to sigmoidoscopy: What is the added yield? (2000) (3)
Abstract CT083: Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma (2017) (3)
Molecular and immune predictors of response and toxicity to combined CTLA-4 and PD-1 blockade in metastatic melanoma (MM) patients (pts). (2017) (3)
Tumor and systemic immune responses to preoperative (pre-op) cryoablation (cryo) plus immune therapy with ipilimumab (ipi) in early-stage breast cancer (ESBC). (2014) (3)
Lymphocyte activation and effector functions. How signals are integrated in the immune system. (1997) (3)
Treg infiltration and the expression of immune checkpoints associated with T cell exhaustion in AML. (2018) (3)
Linking tumor mutational load to clinical responses to ipilimumab (IPI) in men with advanced prostate cancer (PCa). (2017) (3)
A novel strategy for the generation of T cell lines lacking expression of endogenous alpha- and/or beta-chain T cell receptor genes. (1991) (3)
Molecular and immune heterogeneity in synchronous melanoma metastases (2015) (3)
Fecal immunochemical tests had better sensitivity for detecting colorectal neoplasia in aspirin users than in nonusers (2011) (2)
An exploratory study of nivolumab (nivo) with or without ipilimumab (ipi) according to the percentage of tumoral CD8 cells in advanced metastatic cancer. (2021) (2)
Single-cell Characterization of Acute Myeloid Leukemia and its Microenvironment Following PD-1 Blockade Based Therapy (2020) (2)
Biosynthesis of the murine T cell antigen receptor (1984) (2)
Abstract 1493: Therapeutic efficacy and tolerability of combined immune checkpoint blockade in metastatic melanoma patients is influenced by the gut microbiome (2019) (2)
Prognostic implications of TAMs in colorectal cancer hepatic metastases. (2017) (2)
T CELLS WITH INVARIANT yb ANTIGEN RECEPTORS (1991) (2)
Cytokine changes in castrate metastatic prostate cancer (CPMC) patients (pts) treated with ipilimumab (Ipi). (2009) (2)
An immune adsorption technique for analysis of antigenic determinants reacting with HLA antisera. (1977) (2)
Chemokines and recruitment of regulatory T cells to the tumor (40.14) (2009) (2)
Abstract PR01: Blocking Colony Stimulating Factor 1 Receptor (CSF-1R) and Tropomyosin Receptor Kinase (Trk) improves antitumor efficacy of immunotherapy (2017) (2)
James P. Allison-Nobel Lecture: Immune Checkpoint Blockade in Cancer Therapy (2021) (2)
Abstract 592: Distinct cellular mechanisms mediate anti-CTLA-4 and anti-PD-1 checkpoint blockade (2017) (2)
Part 5: Targeting Cancer Pathways: Understanding Immune Checkpoints (2016) (2)
Molecular characterization of the murine T cell antigen receptor and associated structures. (1985) (2)
Abstract P4-13-01: A pilot study of pre-operative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early stage/resectable breast cancer (ESBC) (2013) (2)
rearrangement and cell lineages (1987) (2)
Combination therapy of adoptive T cell therapy and immune checkpoint blockades engages distinct mechanisms in CD4+ and CD8+ T cells (2018) (2)
The major histocompatibility complex-restricted antigen receptor on T cells in mouse and man: identification of constant and variable peptides. 1983. (2006) (2)
Negative costimulation constrains T cell differentiation (2018) (2)
Abstract CT131: NCI#9673 phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal: Immunologic correlates of response (2016) (2)
Cancer: Editorial overview (2000) (2)
Responses through a CD 28B 7-Dependent CTLA-4 Overexpression Inhibits T Cell (2006) (2)
Abstract A146: Increase antitumor activity of immunotherapy by blocking colony stimulating factor 1 receptor and tropomyosin receptor kinase (2016) (2)
Evaluation of soluble B7x as a serum marker in patients with clear cell renal cell carcinoma (2008) (2)
CTLA-4 BLOCKADE IN TUMOR IMMUNOTHERAPY (2005) (2)
Immune correlates in a Phase II clinical trial with ipilimumab in combination with finite androgen deprivation therapy in patients with metastatic non-castrate prostate cancer (2015) (2)
IS SEROLOGICAL POLYMORPHISM OF HUMAN DR ANTIGENS DETERMINED BY STRUCTURAL DIFFERENCES IN THE SMALLER (β) CHAIN (1979) (2)
Investigation of mechanisms of resistance to ipilimumab therapy with a pre-surgical trial in patients with high-risk, localized prostate cancer. (2017) (2)
S1615 SAFETY, EFFICACY, AND BIOMARKERS OF RESPONSE TO AZACITIDINE (AZA) WITH NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI), AND AZA WITH NIVO IN R/R ACUTE MYELOID LEUKEMIA: A NON-RANDOMIZED, PHASE 2 STUDY. (2019) (2)
Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors (2014) (2)
Rising Use of Multitarget Stool DNA Testing for Colorectal Cancer. (2021) (2)
Association of the T-cell receptor landscape with survival in non-small cell lung cancer. (2018) (2)
MONOCLONAL ANTIBODY TO TUMOR SPECIFIC EPITOPE OF MURINE LYMPHOMA CELLS: USE IN CHARACTERIZATION OF ANTIGEN AND IN IMMUNOTHERAPY (1983) (2)
Kinetics of the reaction of metal alkyl compounds with alkenes. Part 1.—Aluminium triethyl and n-1-hexene (1963) (2)
Colorectal-cancer screening. (2012) (2)
OA20.06 Prospective ImmunogenomiC PrOfiling of Non-Small Cell Lung Cancer - The ICON Project (2017) (2)
Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. 1982. (2005) (2)
Sumisu−Sensei Nikki, or Sumisu Koumu Nenshi, Sarah C. Smith's Annual Report on School Affairs (2012) (2)
The impact of prior radiation therapy on outcome in a phase 2 trial combining sipuleucel-T (SipT) and ipilimumab (Ipi) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). (2021) (1)
Introduction: gamma delta T cells--the 'other' T lymphocytes. (1991) (1)
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma (2020) (1)
Matched T cell repertoire analysis of peripheral blood and tumor-infiltrating lymphocytes (TILs) in early stage breast cancer (ESBC) patients (pts) treated with pre-operative cryoablation (cryo) and/or Ipilimumab (Ipi) (2014) (1)
Abstract 1786: Improved survival with gemcitabine and CTLA-4 blockade in a murine model of prostate cancer (2011) (1)
Phenotypic characterization of allogeneically transplanted oval cells (1985) (1)
Novel mulv env gene products are not required for lymphomagenesis in c57bl/6 mice. Abstr. (1983) (1)
P1.05-028 Phenotypic and Functional Profiling of Tumor-Infiltrating Lymphocytes (TIL) in Early Stage Non-Small Cell Lung Cancer (NSCLC): Topic: Translational Research and Biomarkers (2017) (1)
Cytotoxic T lymphocyte antigen-4 ( CTLA-4 ) regulates the size , reactivity , and function of a primed pool of CD 4 1 T cells (2000) (1)
Durable Responses with Ipilimumab Plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies (2018) (1)
CTLA-4 blockade induces effective anti-tumor immunity without significant autoimmunity in previously vaccinated patients (2006) (1)
Abstract PR08: Metabolic adaptations establish immunotherapy resistance in melanoma (2018) (1)
Blocking colony stimulating factor 1 receptor (CSF-1R) and tropomyosin receptor kinase A (TrkA) improves the antitumor efficacy of immune checkpoint blockade (2018) (1)
Abstract IA08: Immune checkpoint blockade in cancer therapy: New insights, opportunities, and prospects for cures (2017) (1)
Potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus. (2014) (1)
Chronic inflammatory liver disease in mice expressing a CD28-specific ligand (P4099) (2013) (1)
Abstract 3570: Adoptive transfer of tumor antigen-specific CTLs requires anti-CTLA-4 and anti-PD-1 to drive tumor eradication (2018) (1)
Pillars Article: The Major Histocompatibility Complex-restricted Antigen Receptor on T Cells in Mouse and Man: Identification of Constant and Variable Peptides. Cell 1983; 35: 295–302. (2006) (1)
Immune checkpoint therapy: Forging ahead (2022) (1)
Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection (2013) (1)
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma (2017) (1)
OA 13.05 Immune, Molecular and T Cell Repertoire Landscape of 235 Resected Non-Small Cell Lung Cancers and Paired Normal Lung Tissues (2017) (1)
Abstract OT3-1-01: A pilot study of single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer scheduled for mastectomy (2012) (1)
Erratum: B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via R-T interactions (Journal of Immunology (2004) 172 (34-39)) (2004) (1)
Should recommendations for colorectal-cancer screening be changed? (2007) (1)
a / fJ T-cell antigen receptor gene and protein expression occurs at early stages of thymocyte differentiation (2003) (1)
Abstract A084: High OX-40 expression on the tumor immune infiltrate is a prognostic factor of better survival in non-small cell lung cancer (2016) (1)
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. (2016) (1)
Carcinoma and anemia (1986) (1)
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma (2023) (1)
Cytotoxic T Lymphocyte Antigen-4 Blockade Enhances Antitumor Immunity by Stimulating Melanoma-Specific (2014) (1)
Quantitation of Hemoglobin Makes Fecal Immunochemical Tests a Better FIT for Non-Invasive Screening (2013) (1)
Sarah Smith's Final Years (2007) (1)
Blockade of CTLA-4 combined with a GM-CSF vaccine cures mice from the highly tumorigenic, poorly immunogenic melanoma B16-BL6, and induces skin depigmentation (1998) (1)
Health care costs of a test and treat intervention for H. pylori in chronic peptic ulcer disease: A randomized controlled trial in a large health maintenance organization (2000) (1)
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial (2023) (1)
MA11.09 Increased Frequency of Bystander T Cells in the Lungs Is Associated with Recurrence in Localized Non-Small Cell Lung Cancer (2019) (1)
Combinatorial biomarkers to predict responses to immune checkpoint therapy in metastatic urothelial cancer. (2021) (1)
Acute Pharyngitis Humans and Cynomolgus Macaques with Gene Expression in Streptococcus Group A (2003) (1)
Missionaries Who Worked with Sarah C. Smith (Part I) (2008) (1)
Approach to Screening for Colorectal Cancer (2009) (1)
Patients with Hormone-Refractory Prostate Cancer A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Updated (2007) (1)
Cancer classification using the Immunoscore: a worldwide task force (2012) (1)
Immunochemical fecal occult blood tests for colorectal cancer screening. (2004) (1)
Induction of CNS inflammatory disease as a consequence of CTLA-4/B7 blockade (1998) (1)
Combination of local radiation with CTLA4 blockade: a new approach to the immunotherapy of breast cancer (2003) (1)
Distribution and ontogeny of CD 2 expression (2001) (1)
Expression of a fetal gamma delta T-cell receptor in adult mice triggers a non-MHC-linked form of selective depletion. (1991) (1)
Lymphocyte surface antigens (1985) (1)
Procedure for the selection of HLA xenoantisera for immunochemical characterization of HLA antigens. (1977) (1)
Production of monoclonal antibody to x-ray induced lymphomas: use in characterization of antigen and in immunotherapy. Abstr. (1982) (0)
Abstract P2-14-14: Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2 negative stage II-III breast cancer (2022) (0)
Expanding Access to Hokusei Gakuen Historical Materials : Creating a Web Site Display of Hokusei-related Reports to the General Assembly of the Presbyterian Church in the United States of America (2011) (0)
Ligation via R-T Interactions Immune Responses through CTLA-4 B7 Expression on T Cells Down-Regulates (2003) (0)
T cell-mediated tumor immunity in a murine model of mammary carcinoma (1996) (0)
Sustained during Chronic Infection T Cells to be + to Injury That Requires CD4 Alternative Activation Is an Innate Response (2007) (0)
IPILIMUMAB PLUS LENALIDOMIDE FOR TREATMENT OF RELAPSED DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (AlloSCT) IN PATIENTS (PTS) WITH LYMPHOID MALIGNANCIES (2019) (0)
Antibody therapy (SY5-2) Chairpersons: Norihiro Nishimoto, Jeffrey V. Ravetch (2010) (0)
PGI1: EFFECTIVENESS OF OMEPRAZOLE, AMOXICILLIN, AND CLARITHROMYCIN IN ERADICATING HELICOBACTER PYLORI IN PATIENTS ON CHRONIC ACID SUPPRESSION FOR PEPTIC ULCER DISEASE OR ULCER-LIKE SYMPTOMS (1999) (0)
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma (2019) (0)
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes (2017) (0)
A feasibility study to determine T cell responses to neoantigens following treatment with ipilimumab in men with metastatic castration-resistant prostate carcinoma (mCRPC). (2016) (0)
Abstract PR003: Single-cell profiling of acute myeloid leukemia (AML) and its microenvironment reveals a CD8 continuum and adaptable T cell plasticity in response to PD-1 blockade-based therapy (2021) (0)
80 Can we give SACT to patients with NSCLC on time and at full dose (2016) (0)
Hokusei Jo Gakko Reports in the Christian Mission Magazine, Woman's Work for Woman (2014) (0)
PP60 Correlation of absolute lymphocyte count with clinical benefit and overall survival: results of compassionate-use trial of ipilimumab in advanced melanoma at Memorial Sloan-Kettering Cancer Center (2009) (0)
B7H3 Expression Correlates with Reduced Infiltration of T cells in Melanoma Tumors and Poor Survival Outcomes (2014) (0)
Abstract 2392: Genomic and immune heterogeneity in synchronous melanoma metastases is associated with differential tumor growth and response to therapy (2016) (0)
Dissociation of Systemic and Local Anti-Tumor Immunity Following Depletion of Regulatory T Cells Limits Therapeutic Activity in Established Tumors. (2007) (0)
Protein Localization in Negative Signaling (2003) (0)
Hokusei Jo Gakko-related Matters in the Minutes of the Meetings of the Japan Mission of the Presbyterian Church in the U.S.A., 1887-1910 (2015) (0)
The Extended CD 28 : B 7 Immunoglobulin Superfamily (2007) (0)
T1090 Flexible Sigmoidoscopy Plus Fecal Immunochemical Testing for Colorectal Cancer Screening: Update with Extended Follow-Up (2008) (0)
Monoclonal Antibodies to Chicken Hemopoietic-Lymphoid Cellular Differentiation Antigens (1983) (0)
Missionary Friends of Sarah C. Smith (2010) (0)
B cells and tertiary lymphoid structures promote immunotherapy response (2020) (0)
H-2 and tumor antigens are physically associated on the surface of murine lymphoma cells. Abstr. (1978) (0)
85 What are the commonest toxicities for patients receiving chemotherapy for NSCLC? – a look at 6 months of data for all comers (2016) (0)
Newly Accessed Research Materials Related to Hokusei Gakuen and Sarah Smith (2006) (0)
Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis (2018) (0)
Defining the Immune Checkpoint Landscape in the Bone Marrow and Peripheral Blood of Patients with Chronic Lymphocytic Leukemia (CLL) (2016) (0)
Abstract 968: Co-occurring genomic alterations define major subsets ofKRAS-mutant lung adenocarcinoma (LUAC) with distinct biology and therapeutic vulnerabilities (2015) (0)
POPULATION-BASED EPIDEMIOLOGY AND CLINICAL CHARACTERISTICS OF PEDIATRIC IBD IN AN INTEGRATED HEALTH PLAN IN NORTHERN CALIFORNIA (2006) (0)
News in brief … (1997) (0)
Abstract 4488: Effector B cells and tertiary lymphoid structures predict response to immune checkpoint blockade in solid tumors (2019) (0)
744 Single cell profiling of acute myeloid leukemia (AML) and its microenvironment reveals a CD8 continuum and adaptable T cell plasticity in response to PD-1 blockade-based therapy (2020) (0)
Abstract 3776: Spatially resolved immunogenomic analyses reveal diverse sub tumoral microenvironments in the context of melanoma immunotherapy (2019) (0)
High-Affinity PD-1 Protein Has Potential. (2015) (0)
An assessment of computer generated space situation map projections (1983) (0)
The Tumor Microenvironment of Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patients (2021) (0)
M1148 Validity of Utilization Data for Predicting Disease Activity in Inflammatory Bowel Disease (2009) (0)
Stimulation de lymphocytes t contre des auto-antigenes au moyen d'agents bloquants ctla-4 (1999) (0)
Racial and Ethnic Differences in Health Care Utilization and Outcomes Among Ulcerative Colitis Patients in an Integrated Health-Care Organization Dan LiBernadette CollinsFernando S. Velayos • Liyan LiuJames D. LewisJames E. AllisonNicole T. Flowers • Susan HutflessOren AbramsonLisa J. Herrinton (2014) (0)
Effectiveness of omeprazole, amoxicillin, and clarithromycin in eradicating Helicobacter pylori in patients on chronic acid suppression for peptic ulcer disease or ulcer-like symptoms (1998) (0)
FEATURED ABSTRACT, Tumor and systemic immune responses to pre-operative cryoablation plus immune therapy with ipilimumab in early stage breast cancer (2015) (0)
A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC) (2019) (0)
Immunologic impact of anti-CTLA-4 therapy. (2009) (0)
Abstract 5711: The impact of combination oral azacitidine (CC-486) + pembrolizumab (PEMBRO) on the immune infiltrate in metastatic melanoma (MM) (2018) (0)
Ralph A. Reisfeld, PhD: In Memoriam (1926–2020) (2021) (0)
Indoleamine 2,3-dioxygenase and T-cell based anti-tumor immunotherapies targeting immune checkpoints (P2010) (2013) (0)
Anti-CTLA4 in the immunotherapy of malignancies (2001) (0)
Erratum: Cutting edge - A crucial role for B7-CD28 in transmitting T help from APC to CTL (Journal of Immunology (2002) 169 (4094-4097)) (2002) (0)
Checkpoint Blockade + Chemotherapy: the Right Combination for AML? (2021) (0)
Effect of murine Vγ3 and Vδ1 antigen receptor transgenes on T cell development (1991) (0)
Stimulation of T cells to self antigens using CTLA-4 inhibitory agents (1999) (0)
Issue Information – TOC ‐ Masthead (2016) (0)
Errata (2001) (0)
Improving the fecal occult-blood test. (1996) (0)
Gene Therapy-Mediated Reprogramming Tumor Infiltrating T Cells Using IL-2 and Inhibiting NF-κB Signaling Improves the Efficacy of Immunotherapy in a Brain Cancer Model (2012) (0)
Lloyd J. Old (1933–2011) (2012) (0)
Abstract P1-08-03: Withdrawn (2018) (0)
Synergistic potentiation of anti-tumor immunity with light-activated drug therapy and anti-CTLA4 antibody treatment. (2011) (0)
An Overview of Primary Source English Language Historical Documents Related to Hokusei Gakuen's Missionary Founders, Part II (2020) (0)
805 Clonal, activated CD8+ T cells recognizing cardiac alpha-myosin drive immune checkpoint inhibitor associated myocarditis in mice (2021) (0)
Incidence of Colorectal Cancer in Inflammatory Bowel Disease: 1132 (2008) (0)
Phase I Trial of MK-3475 and Concurrent Radiation for the Elimination of Extensive-Stage Small Cell Lung Cancer (2018) (0)
IMMUNOGENICITY OF HLA ANTIGENS PURIFIED FROM SERUM1 (1977) (0)
Antibody engineering and mechanisms of action (2011) (0)
Cell Homeostasis The Role of B 7 Costimulation in CD 4 / CD 8 T (2000) (0)
Checkpoint Blockade Therapy (2018) (0)
Abstract 569: MicroRNA-mediated resistance to anti-PD1 therapy in lung cancer (2016) (0)
S1115 Relationship of Aminosalicylate Adherence with Risk of Subsequent Hospitalization or Medication Intensification in Quiescent Ulcerative Colitis (2009) (0)
Abstract IA30: Immune checkpoint blockade in cancer therapy: New insights and opportunities, and prospects for cures (2018) (0)
Lack of regulation by CTLA-4 in the autoimmune NOD mouse (1998) (0)
A rational approach to population screening for colon cancer with colonoscopy: Possible antidote for the downside of the katie couric effect? (2004) (0)
Interleukin-3 Contribute to Insulitis and Destruction of β-Cells Short title: GM-CSF, IL-3 and Diabetes (2013) (0)
Quality Indicators and Benchmarks for Guideline-Recommended Fecal Occult Blood Tests (2015) (0)
Author Index to Volume 228, April-June 1985 (1985) (0)
Mechanisms of negative costimulation by CTLA-4 and its manipulation in tumor immunotherapy in mice and man (2003) (0)
Population-based Studies of Risk Factors in Autoimmunity: The Kaiser Permanente Autoimmune Disease Research Group (KPADRG) (2007) (0)
CD28 disruption exacerbates inﬂammation in Tgf- (cid:1) 1 (cid:1) / (cid:1) mice: in vivo suppression by CD4 (cid:2) CD25 (cid:2) regulatory T cells independent of autocrine TGF- (cid:3) 1 (2004) (0)
Expression of T cell antigen receptor during differentiation (1986) (0)
Cytotoxic T lymphocyte antig expansion of encephalitogen (2016) (0)
Abstract IA19: Immune checkpoint blockade in cancer therapy: New insights and opportunities (2013) (0)
Abstract IA15: Functional diversity of the pancreas tumor stroma (2016) (0)
Immune checkpoint blockade in tumor therapy: new mechanisms and strategies (2008) (0)
FIVE TO TEN YEAR COLON CANCER FREE GUARANTY FOR CLEARING COLONOSCOPY???BUYER BEWARE! (2006) (0)
Gastroenterologists’ Practices and Attitudes Regarding Inflammatory Bowel Disease: 985 (2007) (0)
Expression of Ly-1 and Ly-2 on a spontaneous AKR B-cell lymphoma (2004) (0)
Induced by Androgen Deprivation Augmentation of T Cell Levels and Responses (2004) (0)
Correlation of antigen receptor expression and surface phenotype of murine T-lymphomas (1985) (0)
Role of Adjuvant Sorafenib in Preventing Recurrent Hepatocellular Carcinoma in High Risk Liver Transplantation (2016) (0)
Hindrance of the suppression of T lymphocytes in the context of the CTLA-4 signal transmission (1996) (0)
Structural Analysis of Murine and Human Ia Alloantigens (1978) (0)
M1140 Low Surgery Rates After Diagnosis of Colorectal Dysplasia in Ulcerative Colitis: An Opportunity for Intervention? (2008) (0)
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis (2018) (0)
81 Audit of 1 year survival for patients receiving chemotherapy for NSCLC – all comers (2016) (0)
Creating a Context for Spiritual Formation through Interview Reports at Hokusei Gakuen Women's Junior College, Part II (2004) (0)
Compositions et procedes de modulation de l'activite lymphocytaire (2003) (0)
Abstract 1402: Exploratory biomarkers that predict for clinical outcomes in a Phase II trial with ipilimumab plus finite androgen deprivation therapy for metastatic non-castrate prostate cancer (2016) (0)
Kombinationsimmuntherapie zur krebsbehandlung (2010) (0)
cells β factor and interleukin-3 contribute to insulitis and destruction of Functional deficiencies of granulocyte-macrophage colony stimulating (2013) (0)
Title: A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early- stage breast cancer with comprehensive immune profiling. Authors and affiliations: (2016) (0)
Dissecting the therapeutic effects of anti-CTLA-4 and ADT in a murine hormone-sensitive prostate cancer. (2013) (0)
Prognosis of Dysplasia in Ulcerative Colitis: A Community Cohort Study: 1205 (2009) (0)
Utilization of the Aqueous Mulberry (Morus alba. L.) Leaf Decoction (AMLD) For Treating the DMBA Induced Hepatotoxicity and Free-Radical Damage in Norwegian Rat, Rattus norvegicus (L). (2018) (0)
Abstract #5665: Assessing immunologic impact of anti-CTLA-4 therapy on a pre-surgical clinical trial (2009) (0)
SCREENING FOR COLON CANCER: NO TEST IS PERFECT (2005) (0)
[Biological and chemical aspects of histocompatibility antigens in serum]. (1976) (0)
4-1BB agonist antibody treatment causes intra-tumoral accumulation of KLRG1+ CD8+ and CD4+ T-cells with a novel highly cytotoxic phenotype driven by the master-regulator Eomesodermin (66.17) (2011) (0)
Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy (2020) (0)
Abstract LB-399: Late interferon-gamma blockade improves antitumor efficacy of anti-CTLA-4 and anti-PD-1 combination treatment (2020) (0)
CTLA-4 inhibitors in castration-resistant prostate cancer (2011) (0)
Phase I Trial of MK-3475 and Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer (2018) (0)
Cytotoxic T-lymphocyte-associated Protein 4 and Cancer Therapy (2015) (0)
This information is current as Regulatory T Cells + Foxp 3 Expression of Helios in Peripherally Induced (2011) (0)
Interventional immunotherapy in breast cancer (2012) (0)
Screening for colorectal cancer. (1993) (0)
Congenic mutant recognition of the T cell heteroduplex idiotype on EL4 lymphoma (1984) (0)
Abstract IA20: Immune checkpoint blockade in cancer therapy: New insights and opportunities, and prospects for cures (2020) (0)
Bypass the Pre-TCR Checkpoint Dysregulated CD 28 Costimulation Can Critical for T Cell Development : Regulated Costimulation in the Thymus Is and (2005) (0)
Abstract 499: NanoString®GeoMx®digital spatial profiling further defines the role of B cells in the response to immune checkpoint blockade (2019) (0)
B7-Mediated Co-Stimulation of T Cells: CTLA-4 Can Deliver Inhibitory Signals (1996) (0)
Verfahren und zusammensetzungen für lokalisierte sekretion von anti-ctla-4-antikörpern (2007) (0)
M1150 The Sensitivity and Positive Predictive Value of Computerized Diagnoses, Procedures, and Drugs for Inflammatory Bowel Disease in a Northern California Managed Care Organization (2009) (0)
ATIM-07. WINDOW-OF-OPPORTUNITY CLINICAL TRIAL OF PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA PATIENTS (2018) (0)
Comprehensive T cell repertoire characterization of non-small cell lung cancer (2020) (0)
Checkpoint Blockade and Combinatorial Immunotherapies (2007) (0)
Abstract IA02: Immune checkpoint blockade in cancer therapy: New insights and opportunities, and prospects for cures (2016) (0)
Checkpoint blockade in tumor therapy: New insights and opportunities (2008) (0)
Dissecting the mechanisms of immune checkpoint therapy (2020) (0)
Immune Checkpoint Based Approaches in AML: 031‐MTPIX‐04 (2017) (0)
M1025 Screening for Colorectal Cancer in a Safety-Net Health Care System: Access to Care Is Critical and Has Implications for Screening Policy (2009) (0)
Synergistic potentiation of antitumor immunity with light-activated drug therapy and anti-CTLA4 antibody treatment. (2011) (0)
Abstract 662: Late CTLA-4 Ig treatment improves antitumor efficacy of immunotherapy (2022) (0)
Abstract B143: Fc gamma receptor IV mediated depletionof tumor infiltrating regulatory T cells by anti-CTLA4 antibody is promoted byTLR1/2 agonist and hence its efficacy in anti-tumor combination therapy (2016) (0)
Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. (2022) (0)
Self-reactive CD8 T Cells Pancreas-Specific Damage Mediated by B7x in the Periphery Abrogates (2012) (0)
Evolution of the Leukemic State Group Report (1985) (0)
The congenic mutant B6.C-H-2bm-1 (H-2bm-1) serological response to the T-cell receptor on EL4. (1986) (0)
Tumor-Expressed IDO Rec ruits and Activates MDSCs in a Treg-Dependent Manner Graphical Abstract Highlights (2015) (0)
Abstract B09: TLR1/2 ligand promotes Fc gamma RIV mediated depletion of tumor-infiltrating treg by anti-CTLA-4 antibody and its anti-tumor efficacy (2018) (0)
352 Target modulation within the tumor microenvironment (TME) by daratumumab (anti-CD38) but not edicotinib (CSF-1R inhibitor) in men with high-risk localized prostate cancer (2021) (0)
Receptor-mediated leukemogenesis: Involvement of antigen-specific receptors in retrovirus binding to T cells (1986) (0)
Blockade der T-Lymphozyten-Herunterregelung im Zusammenhang mit der CTLA-4-Signalisierung (1996) (0)
T-cells and cancer immunotherapy ( immuno-oncology ) : the 2018 (2018) (0)
The role of CTLA-4 during the activation of resting CD4+ T-cells☆ (1997) (0)
Vaccination and immunotherapy against bacteria, fungi and parasites (WS-048) Chairpersons: Hajime Hisaeda, Miodrag Colic (2010) (0)
Charge heterogeneity of dipeptidyl peptidase IV (DPP IV) from rat liver, kidney and a hepatocellular carcinoma (1984) (0)
Why What You May Not Know About Fecal Immunochemical Testing Matters (2019) (0)
Transmitting T Help from APC to CTL Cutting Edge: A Crucial Role for B7-CD28 in (2013) (0)
Abstract 4149: Anti-CTLA-4 generates memory T-cells with greater expansion and functionality than anti-PD-1 (2023) (0)
Immune checkpoint therapy—current perspectives and future directions (2023) (0)
Cancer Immunology at the Crossroads: Complementary Therapeutic Modalities Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors? (2014) (0)
Utilization of xeno anti sera to bone marrow derived cell antigens to determine their serological and molecular properties (1977) (0)
Methods for the detection, purification, and biochemical characterization of lymphoid cell surface antigens (1984) (0)
Helicobacter pylori status of patients on chronic acid suppression for peptic ulcer disease or ulcer like symptoms (1998) (0)

This paper list is powered by the following services:

Other Resources About James P. Allison

What Schools Are Affiliated With James P. Allison?

James P. Allison is affiliated with the following schools:

James P. Allison's Academic­Influence.com Rankings